Cardioembolic stroke in syndrome of noncompaction cardiomyopathy
https://doi.org/10.30629/2658-7947-2020-25-6-29-34
Abstract
Stroke remains one of the most common diseases and causes of death. Reducing mortality from stroke is in great dependence on the effectiveness of its prevention, which, in turn, is impossible without an accurate understanding of its causes and mechanisms of development. The article represents the history of a patient with ischemic cardioembolic stroke that developed against noncompaction cardiomyopathy, a relatively rare disease that can be diagnosed with the use of available modern research methods. The algorithm for examining a patient with suspected cardioembolic stroke includes long-term Holter monitoring, echocardiography, CT and MRI of the heart, which makes it possible to identify rare causes of cardiac thromboembolism. Postexposure prophylaxis of stroke in such cases is likely to include the use of anticoagulants, but studies aimed to clarify most effective methods of recurrent strokes prevention in rare causes of cardiac thromboembolism are still being conducted.
About the Authors
S. P. Grachev
Moscow State University of Medicine and Dentistry named after A.I. Evdokimov of the Ministry of Health of Russia;
State Clinical Hospital named after I.V. Davydovsky
Russian Federation
Moscow
Russian Federation
Moscow
A. Yu. Botsina
State Clinical Hospital named after I.V. Davydovsky
Russian Federation
Moscow
Russian Federation
Moscow
K. N. Zhuravlev
State Clinical Hospital named after I.V. Davydovsky
Russian Federation
Moscow
Russian Federation
Moscow
M. V. Zamergrad
State Clinical Hospital named after I.V. Davydovsky;
Russian Medical Academy of Continuing Professional Education of the Ministry of Health of Russia
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Feigin V.L., Lawes C.M., Bennett D.A., Anderson C.S. Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol. 2003;2(1):43–53. https://doi.org/10.1016/s1474-4422(03)00266-7
2. Adams H.P.Jr., Bendixen B.H., Kapelle L.J., Biller J., Love B.B., Gordon D.L. et al. Classification of subtypes of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24(1):35–41. https://doi.org/10.1161/01.str.24.1.35
3. Hart R.G., Diener H.C., Coutts S.B., Easton J.D., Granger C.B., O’Donnell M.J. et al. Cryptogenic Stroke/ESUS International Working Group. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol. 2014;13(4):429–38. https://doi.org/10.1016/S1474-4422(13)70310-7
4. Hart R.G., Catanese L., Perera K.S., Ntaios G., Connolly S.J. Embolic Stroke of Undetermined Source: A Systematic Review and Clinical Update. Stroke. 2017;48(4):867–872. https://doi.org/10.1161/STROKEAHA.116.016414
5. Oechslin E., Jenni R. Left ventricular non-compaction revisited: a distinct phenotype with genetic heterogeneity? European Heart Journal. 2011;32(12), 1446–1456. https://doi.org/10.1093/eurheartj/ehq508
6. Biasi G.M., Froio A., Diethrich E.B., Deleo G., Galimberti S., Mingazzini P. et al. Carotid plaque echolucency increases the risk of stroke in carotid stenting: the imaging in carotid angioplasty and risk of stroke (ICAROS) study. Circulation. 2004;110(6):756–62. https://doi.org/10.1161/01.CIR.0000138103.91187.E3
7. Sorimachi T., Nishino K., Morita K., Takeuchi S., Ito Y., Fujii Y. Blood flow changes caused by distal filter protection and catheter aspiration in the internal carotid artery during carotid stenting: evaluation using carotid Doppler sonography. AJNR Am. J. Neuroradiol. 2011;32(2):288–93. https://doi.org/10.3174/ajnr.A2276
8. Hart R.G., Sharma M., Mundl H., Kasner S.E., Bangdiwala S.I., Berkowitz S.D. et al. Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. N. Engl. J. Med. 2018;378(23):2191–2201. https://doi.org/10.1056/NEJMoa1802686
9. Kasner S.E., Swaminathan B., Lavados P., Sharma M., Muir K., Veltkamp R. et al. Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial. Lancet Neurol. 2018;17(12):1053–1060. https://doi.org/10.1016/S1474-4422(18)30319-3
10. Ntaios G., Swaminathan B., Berkowitz S.D., Gagliardi R.J., Lang W., Siegler J.E. et al. NAVIGATE ESUS Investigators. Efficacy and Safety of Rivaroxaban Versus Aspirin in Embolic Stroke of Undetermined Source and Carotid Atherosclerosis. Stroke. 2019;50(9):2477–2485. https://doi.org/10.1161/STROKEAHA.119.025168
11. Diener H.C., Sacco R.L., Easton J.D., Granger C.B., Bernstein R.A., Uchiyama S. et al. RE-SPECT ESUS Steering Committee and Investigators. Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source. N. Engl. J. Med. 2019;380(20):1906–1917. https://doi.org/10.1056/NEJMoa1813959.
Review
For citations:
Grachev S.P., Botsina A.Yu., Zhuravlev K.N., Zamergrad M.V. Cardioembolic stroke in syndrome of noncompaction cardiomyopathy. Russian neurological journal. 2020;25(6):29-34. (In Russ.) https://doi.org/10.30629/2658-7947-2020-25-6-29-34
Views:
1007
Email this article 